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Immunotherapy of human tumour xenografts overexpressing the EGF
receptor with rat antibodies that block growth factor-receptor interaction
H. Modjtahedi, S. Eccles, G. Box, J. Styles & C. Dean
Section ofImmunology, Institute ofCancer Research, Sutton, Surrey, UK.
Sunmmary Athymic mice bearing xenografts of human tumours that overexpress the receptor (EGFR) for
EGF and TGFa have been used to evaluate the therapeutic potential of three new rat monoclonal antibodies
(mAbs) directed against two distinct epitopes on the extracellular domain of the human EGFR. The
antibodies, ICR16 (IgG2a), ICR62 (IgG2b) and ICR64 (IgGl), have been shown (Modjtahedi et al., 1993) to
be potent inhibitors of the growth in vitro of a number of human squamous cell carcinomas because they
block receptor-ligand interaction. When given i.p. at 200fig dose, the three antibodies were found to induce
complete regression of xenografts of the HN5 tumour if treatment with antibody commenced at the time of
tumour implantation (total doses: ICR16, 3.0 mg; ICR62, 1.2 mg; ICR64, 2.2mg). More importantly when
treatment was delayed until the tumours were established (mean diam. 0.5 cm) both ICR16 and ICR62
induced complete or almost complete regression of the tumours. Furthermore, treatment with a total dose of
only 0.44 mg of ICR62 was found to induce complete remission of xenografts of the breast carcinoma
MDA-MB 468, but ICR16 was less effective at this dose of antibody and only 4/8 tumours regressed
completely. ICR16 and ICR62 were poor inhibitors of the growth in vitro of the vulval carcinoma A431, but
both induced a substantial delay in the growth of xenografts of this tumour and 4/8 tumours regressed
completely in the mice treated with ICR62 (total dose 2.2 mg). Although ICR16 and ICR64 were more
effective than ICR62 as growth inhibitors in vitro, ICR62 was found to be substantially better at inducing
regression of the tumour xenografts due perhaps to additional activation of host immune effector functions by
the IgG2b antibody. We conclude that these antibodies may be useful therapeutic agents that can be used
alone without conjugation to other cytotoxic moieties.
The receptor for epidermal growth factor (EGFR) is a
170 kDa transmembrane glycoprotein that has been found to
be overexpressed in many types of human cancer and to be
of prognostic significance in certain types of human malig-
nancy (Harris, 1990a; Gullick, 1991). Furthermore, the find-
ing that malignant cells expressing high numbers of the
EGFR readily form tumours in athymic mice points to a
correlation between transforming potential and the number
of EGFR expressed (Santon et al., 1986; Velu, 1990). Evi-
dence that the receptor is involved in an autocrine loop that
controls growth of these tumours comes also from the find-
ing that many primary tumours co-express both the receptor
and either of the ligands TGFa or EGF (Sporn & Todaro,
1980; Sporn & Roberts, 1985; Derynck et al., 1987; Di
Marco et al., 1989; 1990; Yoshida et al., 1990; Kurachi et al.,
1991).
In cancer patients, the overexpressed receptor may consti-
tute a suitable target on tumours for antibody directed
therapy (Mendelsohn, 1989; Harris, 1990b; Ennis et al.,
1991). Indeed, in certain brain tumours substantial changes
in the external domain of the EGFR have been found as a
consequence ofdeletions in the genes coding for these regions
and the novel junctional sequences formed could provide
tumour specific targets (Steck et al., 1988). Antibodies
directed against growth factor receptors such as the EGFR
can act in more than one way. Firstly they may be able to
inhibit growth by blocking growth factor-receptor interaction
and secondly they may be able to recruit the immune effector
arm of the host to bring about tumour cell destruction. The
latter function which includes activation of complement and
interaction with Fc receptors on effector cells is critically
dependent on antibody isotype.
Over the last decade, a number of monoclonal antibodies
(mAbs) have been raised in mice against the external domain
of the receptor on the human vulval carcinoma A431 (e.g.
Schreiber et al., 1981; Waterfield et al., 1982; Sato et al.,
1983; Fendly et al., 1990). Some of the mouse mAbs have
been shown to inhibit the growth of human tumour cells
when cultured in vitro or when grown as xenografts in
athymic mice (Masui et al., 1984; Rodeck et al., 1987;
Aboud-Pirek et al., 1988; Pellegrini et al., 1991). Also,
clinical trails have been undertaken using some of these
antibodies to the EGFR (EGFR-1, 225 or 425); radioimaging
studies in patients with head and neck cancer (Soo et al.,
1987) and squamous cell lung cancer (Divgi et al., 1991),
radioimaging/radioimmunotherapy trials in patients with
brain gliomas (Kalofonos et al., 1989) or malignant astro-
cytomas (Brady et al., 1991). The results of these clinical
traisl have been promising and point to a role for some
antibodies in the detection and treatment of certain malig-
nancies.
Using two other well characterised human carcinomas that
overexpress the receptor for EGF namely, the head and neck
carcinoma LICR-LON-HN5 (Easty et al., 1981; Cowley et
al., 1986) or the breast carcinoma MDA-MB 468 (Filmus et
al., 1985), we have generated a series of rat mAbs against
four epitopes (A-D) on the external domain of the receptor.
The properties of these antibodies and their effects on the
growth of EGFR-expressing tumour cell lines in vitro have
been described in the accompanying paper (Modjtahedi et
al.) or reported elsewhere (Modjtahedi et al., 1992). The
antibodies that bound to epitopes B, C and D were found to
block the binding of the ligands EGF and TGFa and some
of these (against epitopes C and D) were potent inhibitors of
the growth in vitro of carcinoma cell lines that overexpressed
the receptor for EGF. We report here the results of experi-
ments that show (a) these antibodies also prevent the growth
in athymic mice of xenografts of human tumours that over-
express the receptor for EGF and (b) the isotypes of the
antibody influences the effectiveness of the treatment in vivo.
Materials and methods
Cell lines
The following carcinoma cell lines which express the EGFR
were obtained from Dr M.J. O'Hare: LICR-LON-HN5 (HN5,
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head and neck), MDA-MB 468 (breast), A431 (vulval) and
SKOV3 (ovarian). The cells were cultured routinely in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with a 10% foetal calf and serum and antibiotics. For esta-
blishing xenografts in athymic mice, confluent monolayers of
cells were trypsinised and resuspended at 5 x I07 cellsml-I in
phosphate buffered saline, pH 7.4 (PBS) just before use.
Monoclonal antibodies
Rat monoclonal antibodies ICR16 (IgG2a), ICR62 (IgG2b)
and ICR64 (IgGI) that are directed against the external
domain of the human receptor for EGF were prepared and
purified from ascites as described in the preceding paper
(Modjtahedi et al., 1993). Isotype matched monoclonal anti-
bodies were used as controls namely, ALN/l1/53 (IgG2a)
and 11/160 (IgG2b), that are directed against a specific
antigen on the rat sarcoma HSN (Dean et al., 1984) or
RCI/4/74 (IgGl) an antibody directed against an idiotopic
determinant on ICRl6 (unpublished data).
Effect ofmAbs on the growth oftumour xenografts in athymic
mice
To assess the effect of antibodies ICRl6 and ICR62 on the
growth of tumour xenografts two types of experiment were
performed.
1. Treatment at the time of tumour inoculation 5 x 106
tumour cells in 100jAl of PBS were inoculated subcutaneously
into both flanks of 4 to 5 week old female athymic (nu/nu)
mice. On day 0, groups of four to six mice were treated i.p.
with 200lag of ICR16, ICR62 or ICR64 and further groups
were treated with an equal amount of an isotype matched
control or saline. Treatment was continued for a further 4
consecutive days and, thereafter, three times weekly until the
day indicated for each experiment. Tumours were measured
across two diameters three times weekly and the mean values
determined. When a tumour regressed completely the mean
diameter was taken as zero for calculation of group means
( ± s.d.). Animals were killed when the tumours reached a
mean diameter of 0.8-1 cm and the tumours were excised,
weighed then fixed in formol-saline for histological examina-
tion. Animals in which tumour growth was completely or
partially inhibited were observed for up to 100 days when the
experiments were terminated.
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2. Treatment of established tumours Tumour xenografts
were set up as described above but treatment was delayed
until the tumours had reached a mean diameter of about
0.5 cm. Unless otherwise stated, the protocol for treatment
with antibody was as before and continued until the control
animals were killed.
To compare the effects of treatment on the growth of
individual tumours the average growth rate (GR) was deter-
mined for each tumour. Where the tumours had regressed
completely the results were counted as zero and included in
the calculation.
weight of tumour (mg)
GR (mg/day) = No of days until excision
Results
Treatment with antibody to the EGFR commencing at the time
oftumour inoculation
HN5 tumours In the first experiment, groups of six mice
were treated with antibody ICR16, control antibody ALN/
11/53 or saline. Treatment continued until day 27 when the
control animals were killed because the tumours had reached
a size of 0.8-1.Ocm in diameter. The results presented in
Figure la show that, following a total dose of 3 mg of ICR16
per mouse, all of the tumours regressed and none were
palpable by day 50. No recurrence of the tumours was
Figure 1 Effect on the growth of HN5 xenografts of treatment
of athymic mice with a, ICR16 (a) or ALN/11/53 (a) from day
0-27 (total dose 3.0 mg/mouse); b, ICR62 (M) or ALN/11/53
(0) from day 0-7 (total dose 1.2mg/mouse); c, ICR64 (M) or
RCI/4/74 (0) from day 0-18 (total dose 2.2mg/dose).
observed in any of the mice treated with ICR16 and the
experiment was terminated at day 90. The growth of HN5
tumours was not affected by treatment with the control
antibody ALN/11/53 and the results were not significantly
different from the controls given PBS only.
Antibody ICR62 binds to the same epitope (C) as ICR16
but is of different isotype (IgG2b). When a group of five
HN5-bearing athymic mice were treated with this antibody
(200pLg/treatment i.p.) no tumours were palpable at seven
out of the ten sites by day 7 (Figure lb) so treatment with
antibody was discontinued (total dose 1.2mg). Tumours in
the controls treated for the same time with ALN/11/53 con-
tinued to grow as shown in Figure lb. The three tumours
palpable at day 7 in the ICR62 treated mice regressed rapidly
and no tumour recurrence was observed in any of the
animals by day 90 when the experiment was terminated.
In a third experiment, mice bearing HN5 tumours were
treated from the time of tumour inoculation with a third
antibody, ICR64 (IgGl), that is directed against a different
epitope (D) on the EGFR. This antibody, together with
ICR16, had been found to be the most effective inhibitor of
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the growth of HN5 cells in vitro. Again, treatment with this
antibody was effective in causing the regression of HN5
xenografts in mice that had been treated with an i.p. dose of
200jig ICR64 from day 0 to day 18 (total dose/mouse of
2.2 mg). All of the tumours had regressed by day 32 (Figure
1c) whereas in the controls treated with the isotype matched
control antibody RCI4/74 the tumours had reached a mean
diameter of 0.76 cm at day 14.
We conclude that all three antibodies, delivered by intra-
peritoneal injection, could inhibit completely the growth of
HN5 cells in the flanks of athymic mice when the treatment
was commenced at the time of tumour implantation.
A431, MDA-MB 468 and SKOV 3 tumours
To investigate the effect of these antibodies on the growth in
vivo of EGFR overexpressing tumours of different origin,
experiments were set up using athymic mice bearing xeno-
grafts of the A431, MDA-MB 468 or SKOV3 tumours. It
should be noted that the SKOV3 tumour while expressing
the EGFR also overexpresses the product of the c-erbB-2
proto-oncogene at a substantially higher level. The total dose
of antibody administered to the mice in each group was
2.2 mg/mouse in the experiments with the A431 and SKOV3
tumours and 0.44 mg with the MDA-MB 468 tumour.
In the first experiment using A431 xenografts, tumours
were detected at 7/8 sites by day 3 in the control animals
(Group A) and the tumours grew progressively until day 11
when these animals were killed. In group C, treated with
ICR16 (Figure 2), tumours were palpable at 6/10 sites by day
11 and by day 21 tumours were growing slowly but progres-
sively at all sites. As in the experiments with the HN5
tumour, antibody ICR62 (Group B) was found to be more
effective compared with ICR16 in inhibiting the growth of
A431 xenografts. Tumours were palpable at 4/10 sites by day
11 and 5/10 sites by day 21 and when the experiment was
terminated at day 51 four of the original ten sites were
tumour free. We conclude that treatment from day 0 to day
18 with a total dose of 2.2 mg/mouse of either ICR16 or
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ICR62 produced a substantial delay in the growth of the
A431 tumour and that of the two antibodies, ICR62 was
substantially more effective since growth of 4/10 tumours was
completely prevented.
In the experiments with the MDA-MB 468 xenografts,
tumours were palpable at all sites in the three treatment
groups on day 4, but treatment with antibody ICR62 was
particularly effective in inhibiting the growth of this tumour
(Group B, Figure 3) and all tumours had regressed complete-
ly by day 11. All treatments with antibody were terminated
at day 18 when a total dose of only 0.44 mg had been
administered. In the ICR62 treatment group, no tumour
recurrence was observed when the experiment was terminated
at day 100. While less effective than ICR62, treatment at this
low dose level with ICR16 (Group C) induced the regression
of tumours at 3/8 sites by day 11, 4/8 sites by day 18 and 5/8
sites by day 31 and at the termination of the experiment
(Day 100) 4/8 of the sites remained tumour free.
SKOV 3 cells express substantially lower levels of the
EGFR than do the three tumours described above and none
of the rat antibodies to the EGFR was found to inhibit the
growth of SKOV 3 cells in vitro (Modjtahedi et al., 1993,
accompanying paper). Interestingly, although antibody
ICR16 appeared to be without effect on the growth of this
tumour in vitro, treatment of the xenografted mice with
ICR62 led to a small delay in growth of the tumours (data
not shown). When the experiment was terminated at day 33
the mean growth rates were 11.66 (± 2.64 mg/day) for the
controls, 8.51 (± 2.56 mg/day) for the ICR16 treated mice
and 6.38 (± 2.35 mg/day) for the mice treated with ICR62.
These results indicate that treatment with antibody ICR62
delayed the development of the SKOV 3 xenografts.
The results of these experiments showed that the rat anti-
bodies to the EGFR can totally inhibit or restrict the growth
of several human tumours that overexpress this receptor.
Furthermore, the experiments with the MDA-MB 468 tumour
suggest that the total dose of antibody required to induce
these effects may be substantially less than that used (3.0 mg)
in the initial experiments with the HN5 tumour xenografts.
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Figure 2 Growth of A431 xenografts in athymic mice treated from day 0-18 with a, ALN/1 1/53, b, ICR62, c, ICR16 (total dose
of antibody 2.2 mg/mouse. Site without tumour (0), site with tumour (0), mouse killed (U, tumours >0.8 cm diameter).
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Figure 3 Growth of MDA-MB 468 xenografts in athymic mice treated from day 0-18 with a, ALN/11/53, b, ICR62, or c, ICR16
(total dose 0.44 mg/mouse). Site without tumour (0), site with tumour (0), mouse killed (A, tumours >0.8 cm diameter).
mm
NON.
MON. mm MON. mem.
1.00 I;.- I I
0.80-
0
L-
@ 0.60-
E
.C
0
E
= 0.40-
Cu
0.20
0
0
0
0
0
0
0
000
a
0
0
0
0
I
0
000
I
000
OU.IA __ _ _ _ __ _ _ _
a b
Day
a b
31
a b
52
000
a b
100
Figure 4 Effect of treatment with low doses of ICR62 on the growth of HN5 xenografts. Athymic mice were treated from day
0-18 with a total dose of 110 g of a, ALN/11/53 or b, ICR62. Site without tumour (0), site with tumour (0), mouse killed (U,
tumours >0.8 cm diameter).
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Effect oftreatment with low doses ofICR62 on the growth of
HNS xenografts
When mice bearing xenografts of HN5 tumours were treated
with lOlg doses of ICR62 from day 0-18 (total dose 0.11
mg) no tumours grew at 3/8 sites and the rate of tumour
growth was restricted at the other sites compared with con-
trols treated with the same dose of ALN/11/53 (Figure 4).
These results show that this IgG2b antibody could affect
tumour growth at a dosage which was some 30 fold lower
than that used in the initial experiments with the HN5
tumour.
Antibodies ICR16 and ICR62 cause regression ofestablished
tumours
To investigate the effect of treatment with antibody on the
growth of established, progressively growing tumours, HN5
xenografts were set up and the treatment with antibody was
initiated only when the tumours had reached a mean dia-
meter of 0.5 cm.
Figure 5 illustrates the results obtained following treatment
with ICR16 or ALN/11/53 in which a total dose of 2.6 mg
was given as intraperitoneal injections of 200jig from day 9
until day 32 when the mice in the control group were killed.
Soon after the start of treatment with ICR16 growth of the
HN5 xenografts ceased and the tumours started to regress.
The tumours had regressed completely at 3/12 sites by day 58
and all of the remaining tumours were continuing to regress
45 days after the end of treatment with antibody (day 77)
when the experiment was terminated. The mean weight of the
tumours in the ICR16 treated group at day 77 was 30 mg
compared with a mean value of 300 mg for the tumours in
the control group at day 32.
The effect of ICR62 on the growth of established HN5
tumours is shown in Figure 6. In these experiments two
groups of five mice each were treated with a total dose of
2.2 mg of ICR62 given either as five doses of 400 lsg/animal
from day 6-10 and one of 200pg on day 12 (Figure 6a) or
as 11 doses of 200jtg/animal from day 6-24 (Figure 6b). As
controls, four mice were treated with 2.2 mg of antibody
11/160 (IgG2b) and two mice were treated with saline alone.
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Progressively growing tumours were detected at all sites by
day 6 and the control animals (Group A) were killed at day
24 when the mean tumour weight was 338.6 mg (Figure 7).
In the two groups treated with ICR62, growth of the
tumours had ceased by day 9 and the tumours commenced to
regress. By day 48 3/10 tumours in Group B and 4/10
tumours in Group C had regressed completely and one fur-
ther tumour in each group had regressed by day 76 when the
experiment was terminated. The mean weights for the
tumours in Group B was 5.17 mg and in Group C was
2.28 mg. We conclude that antibody ICR62 was very effective
in inducing regression of the HN5 tumour xenografts since
9/20 tumours had regressed completely by the end of the
experiment and none of the tumours remaining had a weight
greater than 15.8 mg (Figure 7) compared to a mean tumour
weight in the controls of 338 mg at 21 days. There was little
difference between the two ICR62 treatment groups in either
rate of tumour regression or final result.
Histological examination of the tumours remaining at the
end of the experiment showed that while few viable tumour
cells could be detected numerous keratinised areas were
observed suggesting that only differentiated tissues remained
(data not shown).
Discussion
We are particularly interested in the potential therapeutic
application in cancer patients of antibodies that can inhibit
growth factor-receptor interaction. We have shown (Modjta-
hedi et al., 1993 see accompanying paper) that a number of
rat antibodies raised against the external domain of the
human receptor for EGF were potent inhibitors of the growth
in vitro of tumour cells that overexpress this receptor. In this
paper we demonstrate that three of these antibodies, ICR16
(IgG2a), ICR62 (IgG2b) and ICR64 (IgG1) were also very
effective inhibitors of the growth in athymic mice of several
tumours that overexpress the EGFR. These antibodies, which
were raised against the receptor on either HN5 cells (ICR16)
or MDA-MB 468 cells (ICR62, ICR64), all block the binding
of EGF and TGFa to the EGFR and have been shown to
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Figure 5 Effect on the growth of established HN5 xenografts of treatment of athymic mice from day 9-
2.6mg of ICR16 (-) or ALN/11/53 (0).
-32 with a total dose of
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Figure 6 Effect on the growth of established HN5 xenografts of treatment ofathymic mice with control mAb 11/1160 or saline (@,
group A) or 2.2 mg of ICR62 given as doses of: a, 400iLg from day 6-12 (*, group B) or b, 200iLg from day 6 -24 (U, group C).
inhibit the EGF-induced stimulation of DNA synthesis in
quiescent human fibroblasts (Modjtahedi et al., 1992). It is
most likely that the growth inhibition produced by these
antibodies in vitro is a consequence of blocking growth
factor-receptor interaction.
Antibodies may have an additional function in vivo
because they may be able also to recruit and activate the
effector arm of the host's immune system. These functions
are dependent on antibody isotype and, in the rat, IgG2b
antibodies are particularly effective in this respect (Dyer et
al., 1989). Indeed, the results of these experiments showed
that the antibodies appeared to be more effective at inhibiting
the growth of tumour xenografts than cell proliferation in
vitro. For example, neither ICR16 nor ICR62 could inhibit
completely the growth of MDA-MB 468 or A431 cells in
vitro and they were without effect on SKOV 3 cells. How-
ever, in vivo ICR62 cured all the mice of the MDA-MB 468
tumours when the individual doses were only 40jig and the
total dose given was 0.44 mg. This result is substantially
better than that reported by Mendelsohn (1989) for treat-
ment of this tumour with mAb 528 where complete regres-
sion was not observed even with twice weekly doses of
2 mg/mouse. With the A431 tumour, ICR62 was not as
effective (3/8 tumours cured with a total dose of 2.2 mg) but
treatment resulted in a substantial delay in growth of the
remaining tumours. The latter results do compare favour-
ably, however, with those of other groups using mouse
monoclonal antibodies where for example complete suppres-
sion of A431 growth in athymic mice was reported following
treatment with a total dose of 12 mg of mAbs 225 or 528
(Masui et al., 1984).
The higher doses of antibody required to inhibit growth of260 H. MODJTAHEDI et al.
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Figure 7 Weight of tumours from experiment shown in Figure 6. Tumours were excised from control mice at day 21 a; or at day 76
from mice treated with a total dose of 2.2mg ICR62 from day 6-12 b, or 6-24 c.
the A431 tumour may reflect the need to overcome the
blocking effect of circulating antigen because this tumour is
unusual in that the cells secrete large amounts of a truncated
form of the receptor (Weber et al., 1984). Indeed, we have
found that culture supernatants of A431 cells effectively
block the binding of all of the rat antibodies to the receptor
for EGF (Modjtahedi et al., 1993). The success of treatment
clearly depends on antigen density and the results obtained
with the SKOV 3 xenografts suggest that too few receptors
were present to permit effective immune destruction. These
results suggest also that tissues with normal levels of the
EGFR may suffer minimal damage following treatment with
these antibodies. We conclude that the greater effectiveness
of the rat antibodies in vivo is because their activity was not
due solely to receptor blockade and that recruitment of
effector cells played an important role. Masui et al. (1986)
have also reported enhanced activity for a mouse antibody to
the EGFR of the IgG2a isotype (mAb 528) over mAb 225
(IgGl) which bound to the same epitope and they attributed
the greater effectiveness to immune mechanisms involving
macrophages. A similar finding has been reported for
antibody 425 (IgG2a) by Rodeck et al. (1987). Rat antibodies
of the IgG2b isotype have similar properties to mouse IgG2a
antibodies and some have been shown to be particularly
effective in man in mediating antibody dependent cellular
cytotoxicity and activating complement (Hale et al., 1985;
Dyer et al., 1989). These properties may also have cont-
ributed to the superior performance in the xenografted mice
of ICR62 compared to ICR16 or ICR64 whereas the latter
were clearly more effective at receptor blockade. This aspect
is currently under investigation. ICR62 induced tumour
regressions with very low doses of antibody and a total dose
of0.11 mg led to the complete regression of HN5 tumours at
3/8 sites. For this reason we consider mAb ICR62 to be a
serious candidate for clinical application in the treatment of
cancer patients with minimal residual disease where the
tumours overexpress the receptor for EGF.
This work was supported by a Programme Grant awarded by the
Cancer Research Campaign, London.
References
ABOUD-PIRAK, E., HURWITZ, E., PIRAK, M.E., BELLOT, F., SCHLES-
SINGER, J. & SELA, M. (1988). Efficacy of antibodies to epidermal
growth factor receptor against KB carcinoma in vitro and in nude
mice. J. Natl. Cancer Inst., 80, 1605-1611.
BRADY, L.W., MIYAMOTO, C., WOO, D.V., RACKOVER, M., EMRICH,
J., BENDER, H., DADPARVAR, S., STEPLEWSKI, Z., KOPROWSKI,
H., BLACK, P., LAZZARO, B., NAIR, S., McCORMACK, T., NIEVES,
J., MARABITO, M. & ESHLEMAN, J. (1991). Malignant astro-
cytomas treated with iodine-125 labeled monoclonal antibody 425
against epidermal growth factor receptor: a phase II trial. Int. J.
Radiation Oncology Biol. Phys., 22, 225-230.
COWLEY, G.P., SMITH, J.A. & GUSTERSON, B.A. (1986). Increased
epidermal growth factor receptors on human squamous carcin-
oma cell lines. Br. J. Cancer, 53, 223-229.
DEAN, C.J., STYLES, J.M., GYURE, L.A., PEPPARD, J., HOBBS, S.M.,
JACKSON, E. & HALL, J.G. (1984). The production of hybridomas
from the gut associated lymphoid tissue of tumour bearing rats.
I. Mesenteric nodes as a source of IgG producing cells. Clin. Exp.
Immunol., 57, 358-364.
DERYNCK, K., GOEDDEL, D.V., ULLRICH, A., GUTTERMAN, J.U.,
WILLIAM, R.D., BRINGMAN, T.S. & BERGER, W.H. (1987). Syn-
thesis ofmessenger RNAs for transforming growth factor a and P
and the epidermal growth factor receptor by human tumours.
Cancer Res., 47, 707-712.
Di MARCO, E., PIERCE, J.H., FLEMING, T.P., KRAUS, M.H., MOL-
LOY, C.J., AARONSON, S.A. & DIFORE, P.P. (1989). Autocrine
interaction between TGFa and the EGF-receptor: quantitative
requirements for induction of the malignant phenotype. Onco-
gene, 4, 831-838.
DI MARCO, E., PIERCE, J.H., AARONSON, S.A. & DI FIORE, P.P.
(1990). Mechanisms by which EGF receptor and EGFoa cont-
ribute to malignant transformation. Nat. Immun. Cell Growth
Regul., 9, 209-221.
DIVGI, C.R., WEST, S., KRIS, M., REAL, F.X., YEH, D.J., GRALLA, R.,
MERCHANT, B., SCHWEIGHART, S., UNGER, M., LARSON, S.M.
& MENDELSOHN, J. (1991). Phase I and imaging trial of Indium
III - labelled anti-EGF receptor antibody 225 in patients with
squamous cell lung carcinomas. J. Natl. Cancer Inst., 83, 97-104.IMMUNOTHERAPY OF XENOGRAFTED HUMAN TUMOURS 261
DYER, M.J.S., HALE, G., HAYHOE, F.G.J. & WALDMAN, H. (1989).
Effect of campath-I antibodies in vivo in patients with lymphoid
malignancies: influence of antibody isotype. Blood, 73, 1431-
1439.
EASTY, D.M., EASTY, G.C., CARTER, R.L., MONAGHAN, P. & BUT-
LER, L.G. (1981). Ten human carcinoma cell lines derived from
squamous carcinomas of the head and neck. Br. J. Cancer, 43,
772-785.
ENNIS, B.W., LIPMAN, M.E. & DICKSON, R.B. (1991). The EGF
receptor system as a target for anti tumour therapy. Cancer
Invest., 9, 553-562.
FENDLEY, B., WINGET, M., HUDZIAK, R.M., LIPARI, M.T., NAPIER,
M.A. & ULLRICH, A. (1990). Characterization of murine mono-
clonal antibodies reactive to either the human epidermal growth
factor receptor or HER2/neu gene product. Cancer Res., 50,
1550-1558.
FILMUS, J., POLLAK, M.N., CAILLEAU, R. & BUICK, R.N. (1985).
MDA-468, a human breast cancer cell line with a high number of
epidermal growth factor (EGF) receptors, has an amplified EGF
receptor gene and is growth inhibited by EGF. Biochem. Biophys.
Res. Comm., 128, 898-905.
HALE, G., CLARK, M. & WALDMANN, H. (1985). Therapeutic poten-
tial of rat monoclonal antibodies: isotype specificity of antibody
dependent cell mediated cytotoxicity with human lymphocytes. J.
Immunol., 134, No. 5, 3056-3061.
HARRIS, A.L. (1990a). Epidermal growth factor receptor (EGFr).
Expression in human primary cancers. Proc. Am. Assoc. Cancer
Res., 31, 458-460.
HARRIS, A.L. (1990b). The epidermal growth factor receptor as a
target for therapy. Cancer Cells, 2, 321-323.
GULLICK, W.J. (1991). Prevalence of aberrant express of the epider-
mal growth factor receptor in human cancers. Br. Med. Bull., 47,
87-98.
KALOFONOS, H.P., PAWLIKOWSKA, T.R., HEMINGWAY, A., COUR-
TENAY-LUCK, N., DHOKIA, B., SNOOK, D., SIVALAPENKO, G.B.,
HOOKER, G.R., MCKENZIE, C.G., LAVENDER, P.J., THOMAS,
D.C.T. & EPENETOS, A.A. (1989). Antibody guided diagnosis and
therapy of brain gliomas using radiolabelled monoclonal anti-
bodies against epidermal growth factor receptor and placental
alkaline phosphatase. J. Nucl. Med., 30, 1636-1645.
KURACHI, H., MORISHIGIE, K., ADACHI, H., HIROTA, K., MIYKA,
A. & TANIZAWA, 0. (1991). Importance of TGFa/EGFR auto-
crine mechanism in an ovarian cancer cell line in vivo. Cancer
Res., 51, 5956-5959.
MASUI, H., KAWAMOTO, T., SATO, J.D., WOLF, B., SATO, G. &
MENDELSOHN, J. (1984). Growth inhibition of human tumour
cells in athymic mice by anti-epidermal growth factor receptor
monoclonal antibodies. Cancer Res., 44, 1002-1007.
MASUI, H., MOROYAMA, T. & MENDELSOHN, J. (1986). Mechanism
of antitumour activity in mice for anti-epidermal growth factor
receptor monoclonal antibodies with different isotypes. Cancer
Res., 46, 5592-5598.
MENDELSOHN, J. (1989). Potential clinical application of anti-EGF
receptor monoclonal antibodies. Cancer Cells, 7, 359-362.
MODJTAHEDI, H., STYLES, J., BOX, G., ECCLES, S., GUSTERSON, B.
& DEAN, C. (1992). Antitumour activity of rat Mabs to the
human receptor for EGF. In Mutant Oncogenes: Targets for
Therapy? Epenetos, A.A. & Lemoine, N.R. (eds). Chapman &
Hall, 1992 (in press).
MODJTAHEDI, H., STYLES, J.M. & DEAN, C.J. (1993). The human
EGF receptor as a target for cancer therapy: six new rat MAbs
against the receptor on the breast carcinoma MDA-MB 468. Br.
J. Cancer, 67, 247-253.
PELLEGRINI, R., CENTIS, F., MARTIGNONE, S., MASTROIONNI, A.,
TAGLIBUE, E., TOSI, E., MENARD, S. & COLNAGHI, M.L. (1991).
Characterization of a monoclonal antibody directed against the
epidermal growth factor receptor binding site. Cancer Immuno.
Immunother., 34, 37-42.
RODECK, U., HERLYN, M., HERLYN, D., MOLTHOFF, C., ATKIN-
SON, B., VARELLO, M., STEPLEWSKI, Z. & KOPROWSKI, H.
(1987). Tumour growth modulation by a monoclonal antibody to
the epidermal growth factor receptor: immunology mediated and
effector cell-independent effects. Cancer Res., 47, 3692-3696.
SANTON, J.B., CRONIN, M.T., MACLEOD, C.L., MENDELSOHN, J.,
MASUI, H. & GILL, G.N. (1986). Effect ofepidermal growth factor
receptor concentration on tumorigenicity of A431 cells in nude
mice. Cancer Res., 46, 4701-4705.
SATO, J.D., KAWAMOTO, T., LE, A.D., MENDELSOHN, J., POLIKOFF,
J. & SATO, J.H. (1983). Biological effects in vitro of MAbs to
human EGF receptors. Mol. Biol. Med., 1, 511-514.
SCHREIBER, A.B., LASX, I., YARDEN, Y., ESHHAR, Z. & SCHLESS-
INGER, J. (1981). Monoclonal antibodies against receptor for
epidermal growth factor induce early and delayed effects of
epidermal growth factor. Proc. Natl Acad. Sci. USA, 78, 7535-
7539.
SOO, K.C., WARD, M., ROBERTS, K.R., KEELING, F., CARTER, R.L.,
MCCREADY, V.R., OTT, R.J., POWELL, E., OZANNE, B., WEST-
WOOD, J.H. & GUSTERSON, B.A. (1987). Radioimmunoscinti-
graphy of squamous carcinomas of the head and neck. Head &
Neck Surg., 9, 349-352.
SPORN, M.B. & ROBERTS, A.B. (1985). Autocrine growth factors and
cancer. Nature, 313, 745-747.
SPORN, M.B. & TODARO, G.J. (1980). Secretion and malignant trans-
formation of cells. N. Engl. J. Med., 303, 878-880.
STECK, P.A., LEE, P. & HUNS, W.K. (1988). Expression of an altered
epidermal growth factor receptor by human glioblastoma cells.
Cancer Res., 48, 5433-5439.
VELU, T.J. (1990). Structure function and transforming potential of
the epidermal growth factor receptor. Mol. Cell. Endocrinol., 70,
205-216.
WATERFIELD, M.D., MAYES, E.L.V., STROOBANT, P., BENNET, P.L.P.,
YOUNG, S., GOODFELLOW, P.N., BANTING, G.S. & OZANNE,
B.A. (1982). Monoclonal antibody to the human epidermal growth
factor receptor. J. Cell. Biochem., 20, 149-161.
WEBER, W., GILL, G.N. & SPIES, J. (1984). Production of an epider-
mal growth factor receptor - related protein. Science, 224, 294-
297.
YOSHIDA, K., KYO, E., TSUJINO, T., SANTO, T., NIMOTO, M. &
TAHARA, E. (1990). Expression ofepidermal growth factor trans-
forming growth factor alpha, and their receptor genes in human
gasteric carcinomas; implication for autocrine growth. Jpn. J.
Cancer Res., 81, 43-51.